An observational study in Peripheral Arterial Disease, sponsored by Scitech Produtos Medicos Ltda. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-10.
Sponsored by Scitech Produtos Medicos Ltda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Peripheral Arterial Disease with a site in Brazil — 7 open to participants now, 10 under way, 4 of them phase 3. Peripheral Arterial Disease · Brazil.
Among the 35 studies in Peripheral Arterial Disease with a site in Brazil, this one is one of 2 that started in 2019, is one of 8 observational ones, and was the 15th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 35 studies in Peripheral Arterial Disease with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 15 more countries
Ages 18+
CSL Behring · Sites in Brazil, United States, Argentina and 32 more countries
Ages 18+
Science Valley Research Institute · Sites in Brazil
Population Health Research Institute · Sites in Brazil, United States, Australia and 7 more countries
Ages 18+
University of Nove de Julho · Sites in Brazil
Ages 45+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 11 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 188 across 398 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 90 across the 27 interventional studies, 125 across the 8 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 35 have an industry lead sponsor. The 10 most frequent:
Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Scitech Produtos Medicos Ltda has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Peripheral Arterial Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971772Cardionovum GmbHSIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries | 2026-12 |
| NCT06828172University of Nove de JulhoLocal or Systemic Effects: Mechanisms Related to Arm Crank Exercise - Comparison Between Individuals With and Without PAD | 2027-07-15 |
| NCT06953128Hospital de Clinicas de Porto AlegreGeneral Versus Regional Anesthesia in Peripheral Arterial Surgery | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Peripheral Arterial Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fifty patients will be treated with Solaris Endoprosthesis and followed up to 2 years with Walking Impairment Questionnaire and Doppler Ultrasound evaluation in 30 days, 6 months and 12 months.
Patients with POAD presenting limitant intermitent claudication after 6 months of clinical treatment and patients with rest ischemia, Rutherford class 2 to 5.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device implantation
Device: Endoprosthesis implantation
Endoprosthesis implantation by Percutaneous Angioplasty
Major Adverse Events
MAE is defined as death related to study device/ procedure, Myocardial Infarction, Target Vessel Revascularization or member amputation
Time frame: 1 day
Target Lesion Patency
Stenosis \< 50% and systolic velocity up to 2.5 cm2/s and no TLR
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2019 to primary completion in Apr 2021, 25 months.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 25 months is below that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scitech Produtos Medicos Ltda